Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Reports 2024 Financial Results and Key Developments
Summary
On March 20, 2025, Terns Pharmaceuticals, Inc. reported its financial results for the year ended December 31, 2024, and provided updates on its clinical pipeline. The company announced positive interim data from the Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML), with compelling molecular responses and an encouraging safety profile. Additionally, the first patient was enrolled in the Phase 2 FALCON trial of TERN-601 for obesity, with 12-week data expected in the fourth quarter of 2025. Terns also reported a cash position of $358 million, expected to support operations into 2028. The company made several leadership appointments, including a new Chief Financial Officer and additions to its board of directors.
Profitelligence Alerts
Get alerts for TERN
Be first to know when Terns Pharmaceuticals Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the discovery and development of novel therapeutic candidates targeting liver disease and oncology. Its primary function is to advance its pipeline of clinical and preclinical drug candidates that address significant unmet medical needs. One of the company's main focuses is on non-alcoholic steatohepatitis (NASH), a progressive liver disease. Through innovative approaches, Terns Pharmaceuticals explores various mechanisms to treat NASH, including small molecules designed to reduce liver inflammation and fibrosis. Beyond liver disease, the company is expanding its platform to include oncology, diversifying its impact in the healthcare industry. As a key player in the biopharmaceutical sector, Terns Pharmaceuticals Inc. contributes to the growing landscape of targeted therapies. With a dedicated emphasis on research and development, the company plays an essential role in pushing the boundaries of treatment options, potentially transforming the management of chronic liver diseases and cancer.
Official SEC Documents
Advertisement